StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Equities researchers at StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report released on Thursday. The brokerage set a “sell” rating on the stock.

Separately, Alliance Global Partners raised their price objective on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, July 22nd.

Tonix Pharmaceuticals Price Performance

TNXP stock opened at $0.15 on Thursday. The business has a 50 day moving average price of $0.33 and a 200 day moving average price of $3.18. The company has a quick ratio of 0.72, a current ratio of 1.15 and a debt-to-equity ratio of 0.13. The stock has a market cap of $3.21 million, a price-to-earnings ratio of 0.00 and a beta of 2.09. Tonix Pharmaceuticals has a fifty-two week low of $0.13 and a fifty-two week high of $24.16.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Friday, August 16th. The company reported ($19.28) earnings per share for the quarter, missing the consensus estimate of ($9.91) by ($9.37). The company had revenue of $2.21 million for the quarter, compared to analysts’ expectations of $3.50 million. Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. Equities research analysts anticipate that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC boosted its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent quarter. Institutional investors and hedge funds own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.